Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes

    ... between endogenous thrombopoietin (THPO) levels and platelet response to romiplostim is unknown. Variables including baseline endogenous THPO levels, transfusion needs, and platelet response were analysed in a randomized trial of 250 thrombocytopenic, ...

    Research Article last updated 08/04/2014 - 8:33am.

  2. Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia

    ... by 3 months post treatment accompanying an increase in platelet counts, but stabilized at the levels higher than normal range. An inverse correlation was noted between TPO levels and platelet counts. The increased plasma TPO levels could be required to maintain ...

    Research Article last updated 10/02/2017 - 9:40am.

  3. Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS

    ... syndromes (MDS) are not defined. Doubling of platelet count at start of second cycle of azacitidine therapy compared to ... follow-up. We found a significant association between platelet count doubling after first cycle of azacitidine therapy and ...

    Research Article last updated 08/04/2014 - 8:37am.

  4. Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience

    ... response (p=0.03). By multivariate analysis, baseline platelet and lymphocyte count predicted for IST response at 3 and 6 ...

    Research Article last updated 09/13/2017 - 7:40am.

  5. Jill Minden’s Encounter with Aplastic Anemia

    ... turned into hospitals, weekly red blood cell and platelet transfusions, and lots of fear. I was treated at Barnes Jewish ...

    Patient Chronicle last updated 09/05/2017 - 10:57am.

  6. Decreased plasma cytokines associate with low platelet counts in aplastic anemia and immune thrombocytopenic purpura

    ... anemia (AA) patients and to be correlated with the platelet count. Objectives: To study the association of CD40L, CXCL5, ... proteins were significantly greater in patients with higher platelet counts than in those with lower platelet counts. In a murine ...

    Research Article last updated 07/30/2012 - 1:53pm.

  7. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy

    ... Romiplostim can improve platelet counts in about 50% of patients with low- or intermediate 1-risk ... of romiplostim in 60 patients with lower risk MDS and platelet counts ≤50 × 109 /l. The primary endpoint was adverse event (AE) ...

    Research Article last updated 07/11/2017 - 10:22am.

  8. Platelet drug shows clinical benefits for severe, unresponsive aplastic anemia

    ... well as stimulate increased production of platelets from platelet precursor cells. How is it given and for how long? ...

    Interview last updated 07/06/2012 - 3:42pm.

  9. Outcomes and healthcare utilization in children and young adults with aplastic anemia: A multiinstitutional analysis

    ... interval [CI] 0.6-2.58, P = 0.567), while every platelet transfusion was associated with higher mortality (OR 1.37, 95% CI ...

    Research Article last updated 07/18/2017 - 10:32am.

  10. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.

    ... and severe thrombocytopenia. Patients with a stable platelet count of lower than 30 × 109 platelets per L, aged at least ... endpoints were the proportion of patients achieving a platelet response within 24 weeks and safety. The interim analysis presented ...

    Research Article last updated 02/21/2017 - 9:49am.